Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Somewhat Bullish +50

Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect

📅 Vertex Pharmaceuticals is scheduled to release its first-quarter 2026 earnings report on May 4 after the market close.

💰 Analysts have pegged the consensus revenue estimate for the quarter at $2.98 billion.

💵 The consensus earnings per share estimate stands at $4.20 per share.

🏥 Revenue is expected to be driven primarily by strong demand for Trikafta/Kaftrio, with estimated sales of $2.40 billion.

⚠️ Increased Trikafta sales are anticipated to cause further erosion in sales from Vertex's other CF drugs like Symdeko and Orkambi.

💊 Investors will focus on the performance of Alyftrek, which showed sequential growth last quarter and is launching well globally.

🧬 Casgevy gene therapy sales increased significantly due to robust patient growth and improving reimbursement progress.

⚙️ Vertex expects significant 2026 growth in Casgevy as cell collections and product infusions expand.

🩹 Journavx, a non-opioid pain medicine approved in January 2025, showed improved sales driven by strong prescription growth.

⚖️ The company has a mixed earnings history with a positive average surprise of 1.88% over the trailing four quarters.

📉 Vertex shares have declined 6.1% year-to-date, outperforming the industry decline of 1.2%.

🔍 Vertex's current Earnings ESP is negative at -0.54%, making an earnings beat less likely based on recent models.

🏆 Vertex currently holds a Zacks Rank #3 (Hold), which does not increase the odds of an earnings beat.

🔬 The upcoming earnings call will likely include updates on mid- to late-stage pipeline candidates for various diseases.

📉 The last reported quarter featured a negative earnings surprise of 0.79%.

Bullish Signals
  • Vertex's CF franchise continues to grow, driven by strong demand for the blockbuster drug Trikafta/Kaftrio in younger age groups.
  • Alyftrek sales increased sequentially in the last reported quarter, with the U.S. launch progressing well and early launches in Europe showing strong reimbursement access.
  • Casgevy sales increased significantly on a sequential basis in the last quarter due to robust patient growth and rapid progress in drug access and reimbursement.
  • Vertex expects significant growth in Casgevy sales in 2026, supported by positive launch metrics including growing cell collections and product infusions.
  • Journavx (suzetrigine) approved by the FDA in January 2025 saw sequential sales improvements driven by strong prescription growth and favorable early reimbursement progress.
  • Vertex currently carries a Zacks Rank #3, indicating a Hold rating within a model that considers positive earnings potential.
Risk Factors
  • Shares of Vertex have plunged 6.1% year to date, significantly underperforming the industry's decline of just 1.2%, indicating growing investor concern.
  • Vertex has a mixed earnings history, beating estimates in only two of the trailing four quarters while missing on the other two with an average surprise of merely 1.88%.
  • The stock posted a negative earnings surprise of 0.79% in the last reported quarter, highlighting recent difficulties in meeting market expectations.
  • Vertex's Earnings ESP is currently -0.54%, and its Zacks Rank has fallen to #3 (Hold), signaling that the company's fundamentals may be deteriorating relative to peers.
  • The consensus earnings estimate of $4.20 per share is higher than the More Accurate Estimate of $4.18, creating downside risk if analyst upgrades do not materialize.
Full Analysis
Vertex Pharmaceuticals is preparing to release its first-quarter 2026 financial results on May 4, following the market close. Analysts anticipate revenue of approximately $2.98 billion and earnings per share of $4.20. The primary driver for these figures is expected to be continued strong demand for Trikafta/Kaftrio, with consensus estimates pegging its sales at $2.40 billion. However, the report will also highlight potential revenue substitution effects, as higher volumes of the blockbuster cystic fibrosis drug are likely causing erosion in sales of Vertex's other CF medications, including Symdeko/Symkevi, Orkambi, and Kalydeco. Beyond its core franchise, investors will be closely monitoring performance from Alyftrek (vanza triple), a fifth cystic fibrosis medicine that saw sequential sales increases in the previous quarter. Management indicates that the U.S. launch is progressing well across all patient groups, while early adoption in European markets has begun where reimbursement is accessible. Additionally, the company expects significant growth in Casgevy, its one-shot gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia developed with CRISPR Therapeutics. Casgevy sales grew sequentially in the last quarter due to robust patient growth, with 2026 projections suggesting further expansion as cell collections and product infusions rise. Other notable products include Journavx (suzetrigine), a novel non-opioid pain medicine approved by the FDA in January 2025, which demonstrated sequential sales improvements driven by strong prescription growth and favorable reimbursement progress. On a broader portfolio front, Vertex is expected to provide updates on mid- to late-stage pipeline candidates targeting conditions such as acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, and cell therapy for type I diabetes. Historically, VRTX has had a mixed earnings record over the trailing four quarters, beating estimates twice but missing twice for an average surprise of 1.88%, with a negative surprise of 0.79% recorded in the last reported quarter.